Phaseline

Companies › Progentos Therapeutics

Progentos Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Neurology; next expected readout Dec 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
PRO-1562
CNS-penetrant small molecule designed to induce remyelination
–Phase 1Multiple SclerosisDec 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07826689PRO-1562Phase 1Multiple SclerosisNeurologyDec 2028

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.